Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Trading Down 1.4% – Here’s Why

Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF) shares were down 1.4% during trading on Thursday . The company traded as low as C$7.03 and last traded at C$7.10. Approximately 85,827 shares were traded during mid-day trading, an increase of 1,058% from the average daily volume of 7,410 shares. The stock had previously closed at C$7.20.

Eupraxia Pharmaceuticals Price Performance

The firm has a 50-day moving average price of C$7.55 and a 200 day moving average price of C$7.10.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (OTCMKTS:EPRXF) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for rare inherited metabolic disorders. The firm’s research platform focuses on developing single-administration treatments designed to address the underlying genetic causes of enzyme deficiencies. Eupraxia’s approach leverages targeted gene delivery to restore or supplement critical metabolic functions in patients with life-threatening conditions.

The company’s lead pipeline candidates include EPRX-101 for Ornithine Transcarbamylase (OTC) deficiency and EPRX-102 for methylmalonic acidemia (MMA), both of which are in preclinical or IND-enabling stages.